KIMS774.00

Krishna Institute of Medical Sciences Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISJUBLPHARMAINDGNONESOURCEPFIZERPOLYMEDMcap ₹30,960 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity14.8215.909.449.44
Return on Assets8.727.233.123.12
Return on Capital Employed14.5312.367.967.96
Return on Invested Capital10.889.196.546.12
Margins
EBITDA Margin25.6425.7920.5419.77
Operating Margin19.7719.9613.2913.29
Incremental Operating Margin20.83-9.99
Pretax Margin18.4118.398.486.49
Net Income Margin13.4513.676.204.61
Net Income to Common Margin12.4212.676.184.85
FCF Margin-5.05-14.07-23.49-23.49
Additional
Effective Tax Rate26.8825.6827.7430.16
Dvd Payout Ratio0.000.0085.62
Sustainable Growth Rate14.8215.901.369.44
Incremental Operating Margin %20.83-9.99-5.39
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.